Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Amylyx Pharmaceuticals, Inc. Common Stock

AMLX

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Last trade $27.18
Day change -$0.62 (-2.23%)
Day range $26.62 – $28.16
Volume 506,552
Market cap $3.57B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.57B
Price / earnings
—
Price / book
4.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-19×

Profitability

Earnings per share
-$1.27
Return on assets
-20.74%
Return on equity
-21.65%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
26.81×
Quick ratio
26.81×
Cash ratio
8.27×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$130.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AMLX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0—
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0—
Selling, general and administrative$21.31M$21.93M$16.17M$15.39M$16.17M$15.64M$15.68M—
Research and development$28.35M$23.77M$27.61M$21.21M$19.86M$27.22M$22.12M—
Total operating expenses$49.66M$45.69M$43.78M$36.61M$36.03M$42.86M$37.8M—
Operating income-$49.66M-$45.69M-$43.78M-$36.61M-$36.03M-$42.86M-$37.8M—
Interest expense$0$0$0$0$0$0$0—
Income before taxes-$45.49M-$43.42M-$41.28M-$32.95M-$34.39M-$41.44M-$35.91M—
Income taxes$0$0$0$46K$0$0$0—
Net income-$45.49M-$43.42M-$41.28M-$33M-$34.39M-$41.44M-$35.91M—
Net income attributable to common shareholders-$45.49M-$43.42M-$41.28M-$33M-$34.39M-$41.44M-$35.91M—
EBITDA-$49.63M-$45.65M-$43.68M-$36.5M-$35.91M-$42.72M-$37.65M$160K
Basic earnings per share-$0.38-$0.39-$0.37-$0.30-$0.37-$0.46-$0.42—
Diluted earnings per share-$0.38-$0.39-$0.37-$0.30-$0.37-$0.46-$0.42—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.

GlobeNewswire Inc.

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Mar 28, 2018$0.4197Apr 2, 2018recurring
Dec 28, 2017$0.3556Jan 2, 2018recurring
Sep 28, 2017$0.2408Oct 2, 2017unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.